EntSun News

Global Respiratory Therapeutics Market US$ 40 Billion by 2023

EntSun News/10744520
Visit the global respiratory therapeutics market by drug class [asthma and COPD - LABA/ICS combination products, leukotriene antagonists, inhaled corticosteroids (ICS), anticholinergics, short acting beta-agonists (SABA), anticholinergics / beta agonists, long acting beta-agonists (LABA), other drug classes]; allergic rhinitis (systemic antihistamines, nasal preparations); by geography and forecast 2015-2023 at https://www.ihealthcareanalyst.com/report/respiratory-therapeutics-market/

The global respiratory therapeutics market report provides market size (Revenue USD Million 2015 to 2023), market share, trends and forecasts growth trends (CAGR%, 2018 to 2023). The global respiratory therapeutics market research report is further segmented by geography into North America (U.S., Canada), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), Latin America (Brazil, Mexico, Rest of LA), and Rest of the World.

The global respiratory therapeutics market report also provides the detailed market landscape (market drivers, restraints, and opportunities), market attractiveness analysis and tracks the major competitors operating in the market by company overview, financial snapshot, key products, technologies and services offered, market share analysis and recent trends in the global market.

More on EntSun News
Major players operating in the global respiratory therapeutics market and profiled in this report include Adams Respiratory Therapeutics, Inc., Allergan plc, AstraZeneca, Boehringer Ingelheim, F. Hoffmann-La Roche, GlaxoSmithKline, Merck & Co., Novartis, Respiratory Therapeutics Group, LLC, and Takeda Pharmaceutical.

1.          Drug Class

1.1.         Asthma and COPD

1.1.1.      LABA/ICS combination products

1.1.2.      Leukotriene antagonists

1.1.3.      Inhaled corticosteroids (ICS)

1.1.4.      Anticholinergics

1.1.5.      Short acting beta-agonists (SABA)

1.1.6.      Anticholinergics / beta agonists

1.1.7.      Long acting beta-agonists (LABA)

1.1.8.      Other drug classes

1.2.         Allergic Rhinitis

1.2.1.      Systemic antihistamines

1.2.2.      Nasal preparations

2.          Geography (Region, Country)

2.1.         North America (U.S., Canada)

2.2.         Europe (U.K., Germany, France, Italy, Spain, Rest of EU)

2.3.         Latin America (Brazil, Mexico, Rest of LA)

2.4.         Asia Pacific (Japan, China, India, Rest of APAC)

2.5.         Rest of the World (Middle East & Africa)

More on EntSun News
3.          Company Profiles

3.1.         Adams Respiratory Therapeutics, Inc.

3.2.         Allergan plc

3.3.         AstraZeneca

3.4.         Boehringer Ingelheim

3.5.         F. Hoffmann-La Roche

3.6.         GlaxoSmithKline

3.7.         Merck & Co.

3.8.         Novartis

3.9.         Respiratory Therapeutics Group, LLC

3.10.       Takeda Pharmaceutical

To request Table of Contents and Sample Pages of this report visit:
https://www.ihealthcareanalyst.com/report/respiratory-therapeutics-market/

About Us

iHealthcareAnalyst, Inc. is a global healthcare market research and consulting company providing market analysis, and competitive intelligence services to global clients. The company publishes syndicate, custom and consulting grade healthcare reports covering animal healthcare, biotechnology, clinical diagnostics, healthcare informatics, healthcare services, medical devices, medical equipment, and pharmaceuticals.

In addition to multi-client studies, we offer creative consulting services and conduct proprietary single-client assignments targeted at client's specific business objectives, information needs, time frame and budget. Please contact us to receive a proposal for a proprietary single-client study.

Contact Us

iHealthcareAnalyst, Inc.

2109, Mckelvey Hill Drive,

Maryland Heights, MO 63043

United States

Email: sales@ihealthcareanalyst.com

Website: https://www.ihealthcareanalyst.com
Show All News | Disclaimer | Report Violation

0 Comments

Latest on EntSun News